Ionis Pharmaceuticals Inc. (IONS)

45.19
NASDAQ : Health Technology
Prev Close 46.35
Day Low/High 44.67 / 47.48
52 Wk Low/High 39.07 / 65.51
Avg Volume 1.17M
Exchange NASDAQ
Shares Outstanding 137.27M
Market Cap 6.36B
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

CARLSBAD, Calif., Aug.

Ionis Reports Second Quarter 2018 Financial Results

Ionis Reports Second Quarter 2018 Financial Results

Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue

IONIS-HTT Rx (RG6042) Granted PRIME Designation By The European Medicines Agency For The Treatment Of People With Huntington's Disease

IONIS-HTT Rx (RG6042) Granted PRIME Designation By The European Medicines Agency For The Treatment Of People With Huntington's Disease

IONIS-HTT Rx is the first and only drug to demonstrate reduction of mutant huntingtin protein, the underlying cause of Huntington's disease, in patients

Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America

Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea -

Interesting IONS Put And Call Options For September 21st

Interesting IONS Put And Call Options For September 21st

Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Ionis Pharmaceuticals To Hold Second Quarter 2018 Financial Results Webcast

Ionis Pharmaceuticals To Hold Second Quarter 2018 Financial Results Webcast

Webcast scheduled for Tuesday, August 7th at 11:30 a.m. Eastern Time

New England Journal Of Medicine Publishes Results From Pivotal Study Of TEGSEDI™ (inotersen) For The Treatment Of Hereditary ATTR Amyloidosis

New England Journal Of Medicine Publishes Results From Pivotal Study Of TEGSEDI™ (inotersen) For The Treatment Of Hereditary ATTR Amyloidosis

-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life-

Ionis Pharmaceuticals Appoints Damien McDevitt As Chief Business Officer

Ionis Pharmaceuticals Appoints Damien McDevitt As Chief Business Officer

CARLSBAD, Calif., June 18, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For A Broad Range Of Neurological Diseases

Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For A Broad Range Of Neurological Diseases

CARLSBAD, Calif., June 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals Larger Than S&P 500 Component Leggett & Platt

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...

Noteworthy Tuesday Option Activity: IONS, PTCT, WAB

Noteworthy Tuesday Option Activity: IONS, PTCT, WAB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ionis Pharmaceuticals Inc , where a total of 10,049 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.1% of IONS's average daily trading volume over the past month of 1.3 million shares.

Biogen's SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead To Improved Motor Function Across A Broad Population Of People Living With Spinal Muscular Atrophy

Biogen's SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead To Improved Motor Function Across A Broad Population Of People Living With Spinal Muscular Atrophy

Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA ® (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy...

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Fight Off Complacency: Cramer's 'Mad Money' Recap (Fri 9/15/17)

Jim Cramer says the market may be shaking off bad news and threats, but recent positivity is unusual. Don't speculate, be diversified and don't feel bad about taking profits.

Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round

Alibaba, Qorvo, Abbott Laboratories, Square: 'Mad Money' Lightning Round

Jim Cramer is bullish on Alibaba, Qorvo, Abbott Laboratories, Square, and Baozun.

Short Interest Increases 12% For IONS

Short Interest Increases 12% For IONS

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,283,370 share increase in total short interest for Ionis Pharmaceuticals Inc , to 12,036,594, an increase of 11.93% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Ionis retained all rights to inotersen and IONIS-FB-LRx as part of reprioritizing its pipeline and a strategic review of its Rare Diseases business.

Short Interest In Ionis Pharmaceuticals Moves 15.8% Lower

Short Interest In Ionis Pharmaceuticals Moves 15.8% Lower

The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,021,584 share decrease in total short interest for Ionis Pharmaceuticals Inc , to 10,753,224, a decrease of 15.82% since 07/14/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D+ (Sell)